PV Bulletin

Mandatory Registration for Medical Devices in Switzerland Starting 1 July 2026

Mandatory registration in swissdamed for medical devices and IVDs replaces existing notification procedures with effect from 1 July 2026.

Primary source: Registration fee

PV Impact Brief

Urgency: HighConfidence: high

What changed

The introduction of mandatory registration in swissdamed from 1 July 2026 replaces prior notification procedures for medical devices and IVDs.

Why it matters

This regulatory change enhances market surveillance and ensures that medical devices comply with safety standards before entering the market.

Action needed

Manufacturers must implement processes for device registration in swissdamed before placing devices on the market, with immediate attention needed for vigilance-reportable incidents.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
ICSRCountry Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Notice
Policy status
effective
Publication date
2026-07-01
Policy change
Mandatory registration in swissdamed for medical devices and IVDs replaces existing notification procedures with effect from 1 July 2026. A transitional period applies until 31 December 2026 for most devices, but registration without a transitional period applies to devices that must be reported to Swissmedic due to serious incidents, FSCAs, or trends.

Key changes

Introduction of mandatory device registration in the swissdamed UDI Devices module; replacement of class I notifications; immediate registration required for vigilance-reportable incidents.

Affected workflows

ICSRCountry Compliance

PV impact

MAHs and manufacturers must use swissdamed for device registration and vigilance-related reporting (incidents, FSCAs, trends) from 1 July 2026 without a transitional period.

View regulator source

Source document details

Exact policy details

Mandatory registration start date
1 July 2026
Applies to: All medical devices, systems, and procedure packs placed on the market in Switzerland.
the introduction of mandatory registration in swissdamed · p. 1 · High · Source
Transitional period end date
31 December 2026
Applies to: Applies to devices, systems, and procedure packs for which sales units are placed on the market after 1 July 2026.
transitional period lasting until 31 December 2026 · p. 1 · High · Source
Registration fee for first device
CHF 200
Applies to: Fee for first UDI-DI registration per year.
A fee of CHF 200 will be charged for the first UDI-DI · p. 1 · High · Source
Registration fee for additional devices
CHF 20
Applies to: Fee for each additional UDI-DI with status 'On the market'.
a flat fee of CHF 20 will be charged for each additional UDI-DI · p. 1 · High · Source
Annual maximum fee
CHF 10,000
Applies to: Cost ceiling per manufacturer per calendar year.
subject to a cost ceiling of CHF 10,000 per calendar year · p. 1 · High · Source
First invoicing date
January 2027
Applies to: For devices registered by 31 December 2026.
The first invoices will be sent from January 2027 · p. 1 · High · Source

Workflow rule impacts

Country ComplianceManufacturer

Manufacturers must adapt their processes to ensure registration before market placement.

Mandatory registration of medical devices in swissdamed

Economic operators must register with Swissmedic before first placing a device on the market · p. 1 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jul 1, 2026

Full briefing

Practical implication

Manufacturers must implement processes for device registration in swissdamed before placing devices on the market, with immediate attention needed for vigilance-reportable incidents.

From 1 July 2026, all medical devices and in vitro diagnostic medical devices must be registered in the swissdamed UDI Devices module. A transitional period allows for registration until 31 December 2026 for most devices, while immediate registration is required for incidents reportable to Swissmedic. The new rules replace class I notifications and introduce a fee structure for registrations. Fees include CHF 200 for the first device and CHF 20 for additional devices, with a maximum of CHF 10,000 charged annually per manufacturer.

What changed: The introduction of mandatory registration in swissdamed from 1 July 2026 replaces prior notification procedures for medical devices and IVDs.

Why it matters: This regulatory change enhances market surveillance and ensures that medical devices comply with safety standards before entering the market.

Practical implication: Manufacturers must implement processes for device registration in swissdamed before placing devices on the market, with immediate attention needed for vigilance-reportable incidents.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated May 23, 2026

MHRA confirms UK clinical trial safety reporting guidance is effective

Urgency: High

Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact4 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guidance
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward